Schulhoff & Co. Inc. Has $499,000 Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Schulhoff & Co. Inc. grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 9.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,055 shares of the company’s stock after purchasing an additional 260 shares during the period. Schulhoff & Co. Inc.’s holdings in Medpace were worth $499,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Joseph Group Capital Management acquired a new position in Medpace during the fourth quarter worth $535,000. Cim LLC grew its position in Medpace by 2.8% during the 1st quarter. Cim LLC now owns 2,570 shares of the company’s stock worth $409,000 after acquiring an additional 69 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in Medpace by 0.7% during the 1st quarter. Los Angeles Capital Management LLC now owns 12,511 shares of the company’s stock valued at $2,047,000 after purchasing an additional 89 shares in the last quarter. Securian Asset Management Inc. raised its position in Medpace by 3.9% in the 4th quarter. Securian Asset Management Inc. now owns 2,646 shares of the company’s stock valued at $576,000 after purchasing an additional 100 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in Medpace by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 7,500 shares of the company’s stock worth $1,201,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 79.70% of the company’s stock.

Medpace Trading Up 0.3 %

Shares of NASDAQ:MEDP traded up $0.46 during mid-day trading on Friday, reaching $165.66. The stock had a trading volume of 246,039 shares, compared to its average volume of 351,600. Medpace Holdings, Inc. has a twelve month low of $126.94 and a twelve month high of $231.00. The firm has a market cap of $5.14 billion, a PE ratio of 28.76 and a beta of 1.43. The firm has a 50 day simple moving average of $151.26 and a two-hundred day simple moving average of $152.54.

Medpace (NASDAQ:MEDP – Get Rating) last released its earnings results on Monday, July 25th. The company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $351.21 million during the quarter, compared to analysts’ expectations of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company’s revenue was up 26.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 6.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. Guggenheim assumed coverage on Medpace in a report on Monday, May 23rd. They issued a “neutral” rating for the company. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, July 28th.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle bought 8,330 shares of the firm’s stock in a transaction that occurred on Monday, July 18th. The shares were acquired at an average cost of $145.00 per share, with a total value of $1,207,850.00. Following the acquisition, the chief executive officer now owns 5,513,639 shares of the company’s stock, valued at $799,477,655. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO August J. Troendle bought 22,290 shares of the firm’s stock in a transaction dated Thursday, July 14th. The shares were bought at an average price of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the transaction, the chief executive officer now owns 5,505,309 shares of the company’s stock, valued at $796,012,628.31. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO August J. Troendle purchased 8,330 shares of the stock in a transaction that occurred on Monday, July 18th. The shares were acquired at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the completion of the transaction, the chief executive officer now owns 5,513,639 shares of the company’s stock, valued at approximately $799,477,655. The disclosure for this purchase can be found here. 20.60% of the stock is currently owned by corporate insiders.

About Medpace

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.